Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies

A phase II study

Ting Chang Chang, Kim Seng Law, Ji Hong Hong, Chyong Huey Lai, Koon Kwan Ng, Suei Hsueh, Lai Chu See, Yu Chen Chang, Chien Sheng Tsai, Hung Hsueh Chou, Kuan Gen Huang, Jui Der Liou, Cheng Tao Lin, Angel Chao, Min Yu Chen, Tzu I. Wu, Shih Ya Ma, Tzu Chen Yen

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

BACKGROUND. During follow-up for patients with cervical carcinoma, elevation of serum squamous cell carcinoma antigen (SCC-Ag) levels in the absence of detectable recurrent lesions presents a diagnostic and therapeutic challenge. In the current prospective study, the authors evaluated the use of fluorine-18-labeled fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) to detect disease recurrence in this setting. METHODS. Women with cervical carcinoma who experienced complete responses to primary treatment or salvage therapy and who had no evidence of recurrent disease as detected by conventional methods but had serum SCC-Ag levels ≥ 2.0 ng/mL on 2 consecutive occasions were eligible for the study. PET was performed within 2 weeks after the completion of conventional studies for the assessment of recurrence. RESULTS. Twenty-seven consecutive patients were registered for the current study. PET findings were positive for 19 patients: 14 who had a distant lesion or lesions, 2 who had a local lesion or lesions, and 3 who had both local and distant lesions. Of these 19 patients, 17 were confirmed to have recurrent disease; the remaining two were found to be free of disease but had severe anthracosis in the PET-positive mediastinal lymph nodes. Seven of the eight patients with negative PET findings were not found to have recurrent disease on follow-up. Overall, PET detected FDG-avid lesions in 17 (94%; P <0.001) of the 18 patients with recurrent disease. Seven of these 18 patients received therapy with curative intent; complete control was achieved in 6, four of whom currently are alive and free of disease. The addition of PET in the current setting curbed the use of futile curative therapy and significantly increased overall survival for patients in the current cohort compared with a historical group of 30 consecutive patients who had elevated SCC-Ag levels as a first sign of recurrence. CONCLUSIONS. PET expedited the detection of recurrent cervical carcinoma in patients with unexplained elevation of SCC-Ag levels. Such expedited detection may have positive effects on patient survival.

Original languageEnglish
Pages (from-to)164-171
Number of pages8
JournalCancer
Volume101
Issue number1
DOIs
Publication statusPublished - Jul 1 2004
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Serum
Neoplasms
Deoxyglucose
Carcinoma
Recurrence
squamous cell carcinoma-related antigen
Anthracosis
Salvage Therapy
Survival
Fluorine
Therapeutics
Lymph Nodes
Prospective Studies

Keywords

  • Cervical neoplasms
  • Computerized tomography
  • Overall survival
  • Positron emission tomography
  • Prospective studies
  • Recurrence
  • Squamous cell carcinoma antigen
  • Treatment outcome

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies : A phase II study. / Chang, Ting Chang; Law, Kim Seng; Hong, Ji Hong; Lai, Chyong Huey; Ng, Koon Kwan; Hsueh, Suei; See, Lai Chu; Chang, Yu Chen; Tsai, Chien Sheng; Chou, Hung Hsueh; Huang, Kuan Gen; Liou, Jui Der; Lin, Cheng Tao; Chao, Angel; Chen, Min Yu; Wu, Tzu I.; Ma, Shih Ya; Yen, Tzu Chen.

In: Cancer, Vol. 101, No. 1, 01.07.2004, p. 164-171.

Research output: Contribution to journalArticle

Chang, TC, Law, KS, Hong, JH, Lai, CH, Ng, KK, Hsueh, S, See, LC, Chang, YC, Tsai, CS, Chou, HH, Huang, KG, Liou, JD, Lin, CT, Chao, A, Chen, MY, Wu, TI, Ma, SY & Yen, TC 2004, 'Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: A phase II study', Cancer, vol. 101, no. 1, pp. 164-171. https://doi.org/10.1002/cncr.20349
Chang, Ting Chang ; Law, Kim Seng ; Hong, Ji Hong ; Lai, Chyong Huey ; Ng, Koon Kwan ; Hsueh, Suei ; See, Lai Chu ; Chang, Yu Chen ; Tsai, Chien Sheng ; Chou, Hung Hsueh ; Huang, Kuan Gen ; Liou, Jui Der ; Lin, Cheng Tao ; Chao, Angel ; Chen, Min Yu ; Wu, Tzu I. ; Ma, Shih Ya ; Yen, Tzu Chen. / Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies : A phase II study. In: Cancer. 2004 ; Vol. 101, No. 1. pp. 164-171.
@article{93560572515b4dd78e3fb4a969e1d99e,
title = "Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: A phase II study",
abstract = "BACKGROUND. During follow-up for patients with cervical carcinoma, elevation of serum squamous cell carcinoma antigen (SCC-Ag) levels in the absence of detectable recurrent lesions presents a diagnostic and therapeutic challenge. In the current prospective study, the authors evaluated the use of fluorine-18-labeled fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) to detect disease recurrence in this setting. METHODS. Women with cervical carcinoma who experienced complete responses to primary treatment or salvage therapy and who had no evidence of recurrent disease as detected by conventional methods but had serum SCC-Ag levels ≥ 2.0 ng/mL on 2 consecutive occasions were eligible for the study. PET was performed within 2 weeks after the completion of conventional studies for the assessment of recurrence. RESULTS. Twenty-seven consecutive patients were registered for the current study. PET findings were positive for 19 patients: 14 who had a distant lesion or lesions, 2 who had a local lesion or lesions, and 3 who had both local and distant lesions. Of these 19 patients, 17 were confirmed to have recurrent disease; the remaining two were found to be free of disease but had severe anthracosis in the PET-positive mediastinal lymph nodes. Seven of the eight patients with negative PET findings were not found to have recurrent disease on follow-up. Overall, PET detected FDG-avid lesions in 17 (94{\%}; P <0.001) of the 18 patients with recurrent disease. Seven of these 18 patients received therapy with curative intent; complete control was achieved in 6, four of whom currently are alive and free of disease. The addition of PET in the current setting curbed the use of futile curative therapy and significantly increased overall survival for patients in the current cohort compared with a historical group of 30 consecutive patients who had elevated SCC-Ag levels as a first sign of recurrence. CONCLUSIONS. PET expedited the detection of recurrent cervical carcinoma in patients with unexplained elevation of SCC-Ag levels. Such expedited detection may have positive effects on patient survival.",
keywords = "Cervical neoplasms, Computerized tomography, Overall survival, Positron emission tomography, Prospective studies, Recurrence, Squamous cell carcinoma antigen, Treatment outcome",
author = "Chang, {Ting Chang} and Law, {Kim Seng} and Hong, {Ji Hong} and Lai, {Chyong Huey} and Ng, {Koon Kwan} and Suei Hsueh and See, {Lai Chu} and Chang, {Yu Chen} and Tsai, {Chien Sheng} and Chou, {Hung Hsueh} and Huang, {Kuan Gen} and Liou, {Jui Der} and Lin, {Cheng Tao} and Angel Chao and Chen, {Min Yu} and Wu, {Tzu I.} and Ma, {Shih Ya} and Yen, {Tzu Chen}",
year = "2004",
month = "7",
day = "1",
doi = "10.1002/cncr.20349",
language = "English",
volume = "101",
pages = "164--171",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies

T2 - A phase II study

AU - Chang, Ting Chang

AU - Law, Kim Seng

AU - Hong, Ji Hong

AU - Lai, Chyong Huey

AU - Ng, Koon Kwan

AU - Hsueh, Suei

AU - See, Lai Chu

AU - Chang, Yu Chen

AU - Tsai, Chien Sheng

AU - Chou, Hung Hsueh

AU - Huang, Kuan Gen

AU - Liou, Jui Der

AU - Lin, Cheng Tao

AU - Chao, Angel

AU - Chen, Min Yu

AU - Wu, Tzu I.

AU - Ma, Shih Ya

AU - Yen, Tzu Chen

PY - 2004/7/1

Y1 - 2004/7/1

N2 - BACKGROUND. During follow-up for patients with cervical carcinoma, elevation of serum squamous cell carcinoma antigen (SCC-Ag) levels in the absence of detectable recurrent lesions presents a diagnostic and therapeutic challenge. In the current prospective study, the authors evaluated the use of fluorine-18-labeled fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) to detect disease recurrence in this setting. METHODS. Women with cervical carcinoma who experienced complete responses to primary treatment or salvage therapy and who had no evidence of recurrent disease as detected by conventional methods but had serum SCC-Ag levels ≥ 2.0 ng/mL on 2 consecutive occasions were eligible for the study. PET was performed within 2 weeks after the completion of conventional studies for the assessment of recurrence. RESULTS. Twenty-seven consecutive patients were registered for the current study. PET findings were positive for 19 patients: 14 who had a distant lesion or lesions, 2 who had a local lesion or lesions, and 3 who had both local and distant lesions. Of these 19 patients, 17 were confirmed to have recurrent disease; the remaining two were found to be free of disease but had severe anthracosis in the PET-positive mediastinal lymph nodes. Seven of the eight patients with negative PET findings were not found to have recurrent disease on follow-up. Overall, PET detected FDG-avid lesions in 17 (94%; P <0.001) of the 18 patients with recurrent disease. Seven of these 18 patients received therapy with curative intent; complete control was achieved in 6, four of whom currently are alive and free of disease. The addition of PET in the current setting curbed the use of futile curative therapy and significantly increased overall survival for patients in the current cohort compared with a historical group of 30 consecutive patients who had elevated SCC-Ag levels as a first sign of recurrence. CONCLUSIONS. PET expedited the detection of recurrent cervical carcinoma in patients with unexplained elevation of SCC-Ag levels. Such expedited detection may have positive effects on patient survival.

AB - BACKGROUND. During follow-up for patients with cervical carcinoma, elevation of serum squamous cell carcinoma antigen (SCC-Ag) levels in the absence of detectable recurrent lesions presents a diagnostic and therapeutic challenge. In the current prospective study, the authors evaluated the use of fluorine-18-labeled fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) to detect disease recurrence in this setting. METHODS. Women with cervical carcinoma who experienced complete responses to primary treatment or salvage therapy and who had no evidence of recurrent disease as detected by conventional methods but had serum SCC-Ag levels ≥ 2.0 ng/mL on 2 consecutive occasions were eligible for the study. PET was performed within 2 weeks after the completion of conventional studies for the assessment of recurrence. RESULTS. Twenty-seven consecutive patients were registered for the current study. PET findings were positive for 19 patients: 14 who had a distant lesion or lesions, 2 who had a local lesion or lesions, and 3 who had both local and distant lesions. Of these 19 patients, 17 were confirmed to have recurrent disease; the remaining two were found to be free of disease but had severe anthracosis in the PET-positive mediastinal lymph nodes. Seven of the eight patients with negative PET findings were not found to have recurrent disease on follow-up. Overall, PET detected FDG-avid lesions in 17 (94%; P <0.001) of the 18 patients with recurrent disease. Seven of these 18 patients received therapy with curative intent; complete control was achieved in 6, four of whom currently are alive and free of disease. The addition of PET in the current setting curbed the use of futile curative therapy and significantly increased overall survival for patients in the current cohort compared with a historical group of 30 consecutive patients who had elevated SCC-Ag levels as a first sign of recurrence. CONCLUSIONS. PET expedited the detection of recurrent cervical carcinoma in patients with unexplained elevation of SCC-Ag levels. Such expedited detection may have positive effects on patient survival.

KW - Cervical neoplasms

KW - Computerized tomography

KW - Overall survival

KW - Positron emission tomography

KW - Prospective studies

KW - Recurrence

KW - Squamous cell carcinoma antigen

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=3042524186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042524186&partnerID=8YFLogxK

U2 - 10.1002/cncr.20349

DO - 10.1002/cncr.20349

M3 - Article

VL - 101

SP - 164

EP - 171

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -